PATENT CLAIM ANALYSIS

Application Number: 15906421
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to the use of a VEGF antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a VEGF antagonist for use in a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops. The invention further provides the use of a VEGF antagonist in the manufacture of a medicament for treating a child having a chorioretinal neovascular or permeability disorder.

Claim (Index 4):
The method of  claim 1 , wherein the child is below the age of 12 and above the age of 1 year.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 88.0
- Lexical Diversity: 2.06557
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13940370', '14972560', '15471506', '14934731', '13140411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7513335163987926
- 35 USC 102 Novelty (BERT): 0.5449956517622805
- Combined Prediction Score: 0.7306997299351414
- Mean Citation Score: 357.29031200000014
- Max Citation Score: 392.6964
- Similarity Product: 215.70891081519127

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test